Literature DB >> 18543101

Nonparametric estimation of mean residual functions.

Musie Ghebremichael1.   

Abstract

Situations frequently arise in practice in which mean residual life (mrl) functions must be ordered. For example, in a clinical trial of three experiments, let e (1), e (2) and e (3) be the mrl functions, respectively, for the disease groups under the standard and experimental treatments, and for the disease-free group. The well-documented mrl functions e (1) and e (3) can be used to generate a better estimate for e (2) under the mrl restriction e (1) < or = e (2) < or = e (3). In this paper we propose nonparametric estimators of the mean residual life function where both upper and lower bounds are given. Small and large sample properties of the estimators are explored. Simulation study shows that the proposed estimators have uniformly smaller mean squared error compared to the unrestricted empirical mrl functions. The proposed estimators are illustrated using a real data set from a cancer clinical trial study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18543101     DOI: 10.1007/s10985-008-9089-x

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  5 in total

1.  Nonparametric estimation of bounded survival functions with censored observations.

Authors:  C I Lee; X Yan; N Z Shi
Journal:  Lifetime Data Anal       Date:  1999       Impact factor: 1.588

2.  Nonparametric tests for comparing two mean residual life functions.

Authors:  E E Aly
Journal:  Lifetime Data Anal       Date:  1997       Impact factor: 1.588

3.  Estimation of two ordered mean residual lifetime functions.

Authors:  N Ebrahimi
Journal:  Biometrics       Date:  1993-06       Impact factor: 2.571

4.  Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort.

Authors:  John Z Ayanian; Alan M Zaslavsky; Charles S Fuchs; Edward Guadagnoli; Cynthia M Creech; Rosemary D Cress; Lilia C O'Connor; Dee W West; Mark E Allen; Robert E Wolf; William E Wright
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.

Authors:  J A Laurie; C G Moertel; T R Fleming; H S Wieand; J E Leigh; J Rubin; G W McCormack; J B Gerstner; J E Krook; J Malliard
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.